Over millions of years, bacteria developed strategies to circumvent our immune system. To fight these bacterial infections, we identify the immune evasion mechanisms and use them against the bacteria.

Our novel mode-of-action operates twofold: it disarms the immune evasion mechanisms of the bacterium. At the same time, the host’s immune system is enabled to tackle the infection.

IMX101 against Helicobacter pylori, currently tested in a clinical phase I trial, is an outstanding example for the next generation of vaccines.